2,4-Diamino-6-morpholin-4-ylpyrimidine-5-carbonitrile | 900473-04-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,4-Diamino-6-morpholin-4-ylpyrimidine-5-carbonitrile
• 英文别名: 2,4-diamino-6-morpholin-4-ylpyrimidine-5-carbonitrile
• CAS: 900473-04-3
• 化学式: C₉H₁₂N₆O
• 分子量: 220.234
• InChiKey: HCYXGFYJUXXRFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  吗啉 、 碳酸胍 、 [双(甲硫基)亚甲基]丙烷二腈 以 吡啶 为溶剂， 反应 3.0h， 以70%的产率得到2,4-Diamino-6-morpholin-4-ylpyrimidine-5-carbonitrile
  参考文献：
  名称：

  One-Pot Synthesis of 6-Substituted Amino-2,4-diaminopyrimidine Derivatives Using Ketene Dithioacetals with Amines and Guanidine Carbonate

  摘要：

  6-Substituted amino-2,4-diaminopyrimidine derivatives were prepared by one-pot synthesis using ketene dithioacetals, amine compounds, and guanidine carbonate in pyridine. These pyrimidine products displayed blue fluorescence in the solid state.

  DOI：

  10.3987/com-08-11587

文献信息

• NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES
  申请人：NAGARATHNAM Dhanapalan

  公开号：US20120289496A1

  公开（公告）日：2012-11-15

  The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了PI3K蛋白激酶调节剂，其制备方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
• US9775841B2
  申请人：——

  公开号：US9775841B2

  公开（公告）日：2017-10-03
• One-Pot Synthesis of 6-Substituted Amino-2,4-diaminopyrimidine Derivatives Using Ketene Dithioacetals with Amines and Guanidine Carbonate
  作者：Yoshinori Tominaga、Miki Hirose、Masayori Hagimori、Yasuhiro Shigemitsu、Naoko Mizuyama、Bo-Cheng Wang

  DOI：10.3987/com-08-11587

  日期：——

  6-Substituted amino-2,4-diaminopyrimidine derivatives were prepared by one-pot synthesis using ketene dithioacetals, amine compounds, and guanidine carbonate in pyridine. These pyrimidine products displayed blue fluorescence in the solid state.